Expression of the translational repressor NAT1 in experimental models of cardiac hypertrophy

S Jeson Sangaralingham, Brian J. Pak, M. Yat Tse, Ekaterini Angelis, Michael A. Adams, C. Smallegange, Stephen C. Pang

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The development of hypertension-induced cardiac hypertrophy is a complex process involving a number of biochemical pathways. In particular, the translation initiation pathway has been postulated to play an important role in controlling cellular growth and proliferation in the cardiovascular system. Recently, a fundamental translational repressor, NAT1 (novel APOBEC target 1 ), has been identified. We have previously shown that NAT1 is developmentally-regulated in the heart of neonatal rats and its expression correlates with periods of rapid cardiac growth. The present investigation was designed to determine whether the expression of NAT1 is modified in the left ventricle of spontaneously hypertensive rats and 2-kidney-1-clip (2K1C) hypertensive rats. Northern blot analysis revealed an increase in NAT1 mRNA expression which correlates with the onset of cardiac hypertrophy. Unlike its pattern of mRNA expression, however, NAT1 protein level did not differ significantly from their respective controls throughout the time course. Interestingly, several protein species ranging in size from approximately 40-70 kDa were detected by Western blotting, in addition to the full length 97 kDa NAT1. Since the NAT1 transcript is a known substrate for the enzyme APOBEC-1 and possibly APOBEC-2, we speculate that these proteins may represent truncated fragments of NAT1 resulting from the formation of premature translation termination codons along the NAT1 transcript by APOBEC editing. Together, these results show that the ventricular expression of NAT1 is regulated at the transcriptional level during the early stages of genetic and 2K1C-induced hypertension and may be involved in the onset of left ventricular hypertrophy.

Original languageEnglish (US)
Pages (from-to)183-190
Number of pages8
JournalMolecular and Cellular Biochemistry
Volume245
Issue number1-2
DOIs
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Cardiomegaly
Rats
Theoretical Models
Cardiovascular system
Messenger RNA
Proteins
Surgical Instruments
Substrates
Enzymes
APOBEC-1 Deaminase
Hypertension
Kidney
Nonsense Codon
Left Ventricular Hypertrophy
Inbred SHR Rats
Growth
Cardiovascular System
Northern Blotting
Heart Ventricles
Western Blotting

Keywords

  • Cardiac hypertrophy
  • Experimental hypertension
  • Gene expression
  • NAT1
  • Translational repressor

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

Expression of the translational repressor NAT1 in experimental models of cardiac hypertrophy. / Sangaralingham, S Jeson; Pak, Brian J.; Tse, M. Yat; Angelis, Ekaterini; Adams, Michael A.; Smallegange, C.; Pang, Stephen C.

In: Molecular and Cellular Biochemistry, Vol. 245, No. 1-2, 03.2003, p. 183-190.

Research output: Contribution to journalReview article

Sangaralingham, S Jeson ; Pak, Brian J. ; Tse, M. Yat ; Angelis, Ekaterini ; Adams, Michael A. ; Smallegange, C. ; Pang, Stephen C. / Expression of the translational repressor NAT1 in experimental models of cardiac hypertrophy. In: Molecular and Cellular Biochemistry. 2003 ; Vol. 245, No. 1-2. pp. 183-190.
@article{a19e5b1d27784fdcb83228e4d4c37a62,
title = "Expression of the translational repressor NAT1 in experimental models of cardiac hypertrophy",
abstract = "The development of hypertension-induced cardiac hypertrophy is a complex process involving a number of biochemical pathways. In particular, the translation initiation pathway has been postulated to play an important role in controlling cellular growth and proliferation in the cardiovascular system. Recently, a fundamental translational repressor, NAT1 (novel APOBEC target 1 ), has been identified. We have previously shown that NAT1 is developmentally-regulated in the heart of neonatal rats and its expression correlates with periods of rapid cardiac growth. The present investigation was designed to determine whether the expression of NAT1 is modified in the left ventricle of spontaneously hypertensive rats and 2-kidney-1-clip (2K1C) hypertensive rats. Northern blot analysis revealed an increase in NAT1 mRNA expression which correlates with the onset of cardiac hypertrophy. Unlike its pattern of mRNA expression, however, NAT1 protein level did not differ significantly from their respective controls throughout the time course. Interestingly, several protein species ranging in size from approximately 40-70 kDa were detected by Western blotting, in addition to the full length 97 kDa NAT1. Since the NAT1 transcript is a known substrate for the enzyme APOBEC-1 and possibly APOBEC-2, we speculate that these proteins may represent truncated fragments of NAT1 resulting from the formation of premature translation termination codons along the NAT1 transcript by APOBEC editing. Together, these results show that the ventricular expression of NAT1 is regulated at the transcriptional level during the early stages of genetic and 2K1C-induced hypertension and may be involved in the onset of left ventricular hypertrophy.",
keywords = "Cardiac hypertrophy, Experimental hypertension, Gene expression, NAT1, Translational repressor",
author = "Sangaralingham, {S Jeson} and Pak, {Brian J.} and Tse, {M. Yat} and Ekaterini Angelis and Adams, {Michael A.} and C. Smallegange and Pang, {Stephen C.}",
year = "2003",
month = "3",
doi = "10.1023/A:1022884515544",
language = "English (US)",
volume = "245",
pages = "183--190",
journal = "Molecular and Cellular Biochemistry",
issn = "0300-8177",
publisher = "Springer Netherlands",
number = "1-2",

}

TY - JOUR

T1 - Expression of the translational repressor NAT1 in experimental models of cardiac hypertrophy

AU - Sangaralingham, S Jeson

AU - Pak, Brian J.

AU - Tse, M. Yat

AU - Angelis, Ekaterini

AU - Adams, Michael A.

AU - Smallegange, C.

AU - Pang, Stephen C.

PY - 2003/3

Y1 - 2003/3

N2 - The development of hypertension-induced cardiac hypertrophy is a complex process involving a number of biochemical pathways. In particular, the translation initiation pathway has been postulated to play an important role in controlling cellular growth and proliferation in the cardiovascular system. Recently, a fundamental translational repressor, NAT1 (novel APOBEC target 1 ), has been identified. We have previously shown that NAT1 is developmentally-regulated in the heart of neonatal rats and its expression correlates with periods of rapid cardiac growth. The present investigation was designed to determine whether the expression of NAT1 is modified in the left ventricle of spontaneously hypertensive rats and 2-kidney-1-clip (2K1C) hypertensive rats. Northern blot analysis revealed an increase in NAT1 mRNA expression which correlates with the onset of cardiac hypertrophy. Unlike its pattern of mRNA expression, however, NAT1 protein level did not differ significantly from their respective controls throughout the time course. Interestingly, several protein species ranging in size from approximately 40-70 kDa were detected by Western blotting, in addition to the full length 97 kDa NAT1. Since the NAT1 transcript is a known substrate for the enzyme APOBEC-1 and possibly APOBEC-2, we speculate that these proteins may represent truncated fragments of NAT1 resulting from the formation of premature translation termination codons along the NAT1 transcript by APOBEC editing. Together, these results show that the ventricular expression of NAT1 is regulated at the transcriptional level during the early stages of genetic and 2K1C-induced hypertension and may be involved in the onset of left ventricular hypertrophy.

AB - The development of hypertension-induced cardiac hypertrophy is a complex process involving a number of biochemical pathways. In particular, the translation initiation pathway has been postulated to play an important role in controlling cellular growth and proliferation in the cardiovascular system. Recently, a fundamental translational repressor, NAT1 (novel APOBEC target 1 ), has been identified. We have previously shown that NAT1 is developmentally-regulated in the heart of neonatal rats and its expression correlates with periods of rapid cardiac growth. The present investigation was designed to determine whether the expression of NAT1 is modified in the left ventricle of spontaneously hypertensive rats and 2-kidney-1-clip (2K1C) hypertensive rats. Northern blot analysis revealed an increase in NAT1 mRNA expression which correlates with the onset of cardiac hypertrophy. Unlike its pattern of mRNA expression, however, NAT1 protein level did not differ significantly from their respective controls throughout the time course. Interestingly, several protein species ranging in size from approximately 40-70 kDa were detected by Western blotting, in addition to the full length 97 kDa NAT1. Since the NAT1 transcript is a known substrate for the enzyme APOBEC-1 and possibly APOBEC-2, we speculate that these proteins may represent truncated fragments of NAT1 resulting from the formation of premature translation termination codons along the NAT1 transcript by APOBEC editing. Together, these results show that the ventricular expression of NAT1 is regulated at the transcriptional level during the early stages of genetic and 2K1C-induced hypertension and may be involved in the onset of left ventricular hypertrophy.

KW - Cardiac hypertrophy

KW - Experimental hypertension

KW - Gene expression

KW - NAT1

KW - Translational repressor

UR - http://www.scopus.com/inward/record.url?scp=0037359233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037359233&partnerID=8YFLogxK

U2 - 10.1023/A:1022884515544

DO - 10.1023/A:1022884515544

M3 - Review article

VL - 245

SP - 183

EP - 190

JO - Molecular and Cellular Biochemistry

JF - Molecular and Cellular Biochemistry

SN - 0300-8177

IS - 1-2

ER -